French Ministry of Health prospective multicentre study using bio-active stents coated with titanium nitride oxide: the EVIDENCE registry
Autor: | Frederic Collet, Bernard Karsenty, Christophe Loubeyre, Antoine Gommeaux, Paul Barragan, Patrick Dupouy, Olivier Wittenberg, Gérard Finet, Philippe Durand, Xavier Tabone, Jean Fajadet, Thierry Unterseeh, Pierre Meyer, Marie-Claude Morice, Marc Silvestri, Benoit Gerardin, Simon Cattan, Michael Angioi, Jean-Marc Lablanche, Marc-Éric Moulichon, Smain Sayah |
---|---|
Rok vydání: | 2011 |
Předmět: |
Male
Percutaneous Time Factors Stents bio-actifs medicine.medical_treatment Native coronary arteries Myocardial Infarction Coronary Angiography Severity of Illness Index Government Agencies Coated Materials Biocompatible Clinical endpoint Myocardial infarction Prospective Studies Registries Angioplasty Balloon Coronary Outcome Aged 80 and over Titanium Résultat clinique Incidence (epidemiology) Bioactive stents General Medicine Middle Aged medicine.anatomical_structure Treatment Outcome Drug Therapy Combination Female Stents France medicine.symptom Cardiology and Cardiovascular Medicine Artery medicine.medical_specialty Prosthesis Design Lesion medicine Humans cardiovascular diseases Aged business.industry Coronary Stenosis Artères coronaires natives Stent Thrombosis equipment and supplies medicine.disease Surgery Titanium-nitride-oxide business Platelet Aggregation Inhibitors |
Zdroj: | Archives of cardiovascular diseases. 105(2) |
ISSN: | 1875-2128 |
Popis: | Summary Background Coronary stents have evolved over time, from bare-metal stents to drug-eluting stents, and now to bioactive stents. Aims We sought to explore the immediate outcome of the titanium-nitride-oxide-coated bioactive stent, Titan2 ® , in real-world practice, and the incidence of major cardiac events at follow-up. Methods Consecutive patients admitted for percutaneous intervention for at least one significant (≥ 50%) lesion in a native coronary artery were treated with Titan2 ® stent implantation. The primary endpoint was total major adverse cardiac events at 12-month follow-up. Secondary endpoints included target lesion revascularization at 12-month follow-up and the duration of dual antiplatelet therapy. Results Among 356 patients (mean age 67.4 ± 12.1 years), 77.2% were male and 39.3% were treated for myocardial infarction (MI). A total of 546 Titan2 ® stents were implanted in 420 lesions. Angiographic and clinical procedural success was achieved in all cases. No cases of in-hospital major adverse cardiac events or acute stent thrombosis were reported. Of 335 patients (94.1%) with 12-month clinical follow-up, four (1.2%) died, MI occurred in five (1.5%), target lesion revascularization was performed in 17 (5.1%) and major adverse cardiac events occurred in 24 (7.2%). One patient (0.3%) suffered late stent thrombosis during follow-up, but no cases of acute or subacute stent thrombosis occurred. Dual antiplatelet therapy continued beyond 6 months in 64.5% of patients. Conclusions In real-world practice, Titan2 ® stent implantation achieves an excellent immediate outcome, with a low incidence of major adverse cardiac events at 12-month follow-up. |
Databáze: | OpenAIRE |
Externí odkaz: |
Pro tento záznam nejsou dostupné žádné jednotky.